Navigation Links
New Research Links Restless Legs Syndrome (RLS) to Cardiovascular Disease

BRUSSELS, April 15, 2011 /PRNewswire/ -- Results from a two-year retrospective cohort study presented at the 63rd Annual Meeting of the American Academy of Neurology (AAN), Hawaii, U.S., showed that patients were significantly more likely to develop cardiovascular (CV) conditions, including hypertension, cardiac dysrhythmias and chronic ischemic heart diseases after an initial diagnosis of RLS, as compared to controls without RLS.

"These findings suggest a significant association between a diagnosis of RLS and subsequent records of major cardiovascular conditions, and build on previous evidence suggesting that RLS may be a risk factor for cardiovascular disease. The findings confirm the need for early diagnosis of RLS so that patients can be monitored for subsequent development of serious cardiovascular events," commented study author, Dr. Florent Richy, Head of Global Epidemiology, UCB and Adjunct Professor of Epidemiology at the University of Liege, Belgium.

The two year retrospective cohort study matched the U.S. medical records of 3,485 RLS patients to those of 3,485 healthy controls. Mean age was 55 years and female/male ratio was 2.34. The study investigated the risk of major CV risk events among patients diagnosed with RLS.  The most frequent CV diagnoses observed were hypertension (48%), cardiac dysrhythmias (9.3%), chronic ischemic heart diseases (8.5%), occlusion and stenosis of cerebral arteries (2.81%), cardiomegaly (2.50%), and hypertensive heart disease (2.43%).

During this two-year observation period, RLS patients had a 12% greater risk of developing any CV event compared to healthy controls (p<0.01). The relative risk (95% CI) for CV events by category were, in decreasing order: other forms (non-ischemic) of cardiovascular diseases, 1.33 (1.20; 1.47); cerebrovascular diseases, 1.31 (1.12; 1.53); disease of the pulmonary circulation, 1.28 (0.86; 1.92); ischemic heart diseases, 1.20 (1.06- 1.35); diseases of the arteries, 1.19 (1.01; 1.43); and hypertension, 0.99 (0.84; 1.03).

About the study

This two-year matched retrospective cohort study was performed on a dataset from a U.S. claims database* containing longitudinal records on demographics, diagnoses, procedures, providers, prescriptions and claims. RLS patients were matched by age, gender and co-morbidities (including hypertension) to healthy controls. CV diagnoses were recorded for a two-year observation period.

* Data Source: IMS LifeLink: Health Plan Claims Database, PharMetrics, Inc., a unit of IMS Health, Watertown, WA. ©2009, All Rights Reserved.

The IMS LifeLink Health Plan Claims Database includes longitudinal, integrated, patient-level medical and pharmaceutical claims comprising five billion patient observations from across the United States comprised of over 70 million patients from over 100 health plans, including medical services and prescription drug information across the entire continuum of care.

Notes to Editors

About Restless Legs Syndrome

Restless Legs Syndrome (RLS) is a neurological disorder characterized by unpleasant sensations in the legs and an uncontrollable urge to move when at rest in order to relieve these feelings. It effects between 3 and 10% of the population to some extent. Most people with RLS have difficulty falling asleep and staying asleep. Left untreated the condition causes exhaustion and daytime fatigue. Many people with RLS report that their job, personal relations and activities of daily living are strongly affected as a result of their exhaustion. They are often unable to concentrate, have impaired memory, or fail to accomplish daily tasks. More than 80% of people with RLS also experience a more common condition known as periodic limb movement disorder (PLMD).

For further information

Nancy Nackaerts, External Communications, UCB
T +32.473.864.414,

Eimear O'Brien, Associate Director, Global CNS Communications UCB
T +32.2.559.9271,

Onsite at Congress

Andrea Levin, Senior Manager, Communications & PR, U.S.
T +770.970.8352,

About UCB

UCB, Brussels, Belgium ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 - Will ... Medical Education (CME) --> - Will ... Continuing Medical Education (CME) --> ... Continuing Medical Education (CME) ... products and services, will feature latest diagnostic imaging textbooks and decision ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Research ... of the "Membranes Market - Global Forecast to ... Asia-Pacific , accounting for 37.21% of the ... Asia-Pacific region is projected to ... This growth has been attributed primarily to the fast ...
(Date:11/25/2015)... 2015 --> ... Lizenz für das Patent über eine neue Hepatitis-B-Behandlung, welches ... innehaben, an Enyo Pharma vergeben haben. Im ... gerufenen und von Edelris gemeinsam mit seinen Partnern Inserm ... für HBV identifiziert, und es wurden neue Inhaltsstoffe entdeckt, ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... American Family Care (AFC), the ... of a holiday pop-up clinic located in Metro Atlanta’s North Point Mall. The clinic ... and different way. The location is scheduled to operate through Dec. 24. , Holiday ...
(Date:11/24/2015)... Danbury, CT (PRWEB) , ... November 24, 2015 , ... ... Network (WCHN) today announced an innovative study designed to yield insights into how to ... potential development of biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Cleveland University-Kansas City (CU-KC), in Overland Park, Kansas. Benson, a fifth-trimester ... University President Carl S. Cleveland III on October 16. , “Katie is very ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Specialty ... Program have announced their endorsement of the Medical Fitness Network (MFN), a ... proud to have the MFN as one of our endorsed organizations,” said ASH ...
(Date:11/24/2015)... ... ... Dr. Kevin Day, local family chiropractor in Warsaw , is hosting a ... During the Indiana winter months, Vitamin D deficiency can lead to Seasonal Affective Disorder ... help provide the tools needed to combat it this year! , “Stress kills us,” ...
Breaking Medicine News(10 mins):